Table 2.
Antihyperglycemic agents prescribed in HF patients with T2DM.
| Classes of | Number of patients (%) | p-valueb | |||
|---|---|---|---|---|---|
| antihyperglycemic | |||||
| agents | |||||
| Totala | HFpEF | HFmrEF | HFrEF | ||
| (n = 101) | (n = 40) | (n = 53) | |||
| Biguanides | |||||
| Yes | 116 (59.8) | 66 (65.3) | 23 (57.5) | 27 (50.9) | 0.211 |
| OR (95% CI) | Reference | 0.72 (0.34–1.52) | 0.55 (0.28–1.08) | ||
| Sulphonylureas | |||||
| Yes | 88 (45.4) | 39 (38.6) | 17 (42.5) | 32 (60.4) | 0.033 |
| OR (95% CI) | Reference | 1.18 (0.56–2.47) | 2.42 (1.23–4.79) | ||
| DPP-4 Inhibitors | |||||
| Yes | 50 (25.8) | 30 (29.7) | 9 (22.5) | 11 (20.8) | 0.420 |
| OR (95% CI) | Reference | 0.69 (0.29–1.62) | 0.62 (0.28–1.37) | ||
| SGLT2 Inhibitors | |||||
| Yes | 4 (2.1) | 1 (1.0) | 1 (2.5) | 2 (3.8) | 0.501 |
| OR (95% CI) | Reference | 2.56 (0.16–42.01) | 0.27 (0.35–44.28) | ||
| α-glucosidase Inhibitors | |||||
| Yes | 1 (0.5) | 0 (0.0) | 0 (0.0) | 1 (1.9) | 0.263 |
| OR (95% CI) | UTC | UTC | UTC | ||
| Insulins | |||||
| Yes | 109 (56.2) | 61 (60.4) | 25 (62.5) | 23 (43.4) | 0.086 |
| OR (95% CI) | Reference | 1.09 (0.51–2.32) | 0.50 (0.26–0.99) | ||
a
a patient may be prescribed with more than one antidiabetic agent;
b
computed by Pearson's Chi-square test; odds ratio (95% CI) computed by Binary Logistic Regression with dummy variable; bolded font indicates statistical significance at p < 0.05. α-glucosidase, alpha-glucosidase; CI, confidence interval; DPP-4, dipeptidyl peptidase-4; HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; OR, odds ratio; SGLT-2, sodium glucose linked transporter-2, UTC, unable to compute.